Business Context and Reporting Period
Pulmatrix, Inc., a Delaware corporation, filed this Form 8-K on March 28, 2018, to report the entry into a material definitive agreement for a public offering of securities. The company is an emerging growth company focused on the research and development of therapeutic candidates, specifically Pulmazole.
Key Financial Metrics and Transaction Details
The filing details a public offering structured as follows:
- Securities Offered: 15,660,000 Common Units and 7,840,000 Pre-Funded Units.
- Unit Composition: Each Common Unit consists of one share of common stock, one Series A warrant, and one Series B warrant. Each Pre-Funded Unit consists of one pre-funded warrant, one Series A warrant, and one Series B warrant.
- Offering Prices: $0.65 per Common Unit and $0.64 per Pre-Funded Unit.
- Overallotment Option: The underwriter, Oppenheimer & Co. Inc., was granted an option to purchase up to 1,150,000 additional Units.
- Expected Net Proceeds: Approximately $13.9 million, excluding proceeds from warrant exercises or the overallotment option.
- Underwriting Compensation: 7% of gross proceeds up to $5.0 million and 6.5% of gross proceeds in excess of $5.0 million.
The filing does not provide historical revenue, profit, cash flow, or debt metrics as this is a current report regarding a specific transaction rather than a periodic financial statement.
Material Changes and Agreements
On March 28, 2018, the Company entered into several material agreements:
- Underwriting Agreement: Executed with Oppenheimer & Co. Inc. for the public offering. Closing is expected on or about April 3, 2018.
- Lock-Up Agreement: The Company agreed not to offer, issue, or sell any shares of common stock or convertible securities for 90 days following March 28, 2018, without Oppenheimer's prior written consent.
- Warrant Waivers: Entered into waiver letters with Polaris Venture Partners, ARCH Venture Fund VII, and Altitude Life Science Ventures. These investors agreed to waive the right to exercise an aggregate of approximately 2.76 million shares underlying their warrants until the Company amends its Certificate of Incorporation to increase authorized shares.
- Option Amendments: Amendments were executed with CEO Robert W. Clarke and CFO William Duke, Jr., restricting the exercise of approximately 1.07 million shares of their stock options until the authorized share count is increased.
Guidance, Outlook, and Use of Proceeds
The Company intends to use the net proceeds from the Offering for the following purposes:
- Research and development of therapeutic candidates, particularly the development of Pulmazole.
- Working capital and general corporate purposes.
The filing does not provide specific financial guidance, risk factors beyond standard transaction contingencies, or commentary on unusual items outside the scope of the offering structure.
Key Facts for Investor Verification
- Verify the final closing date of the Offering, which was expected on or about April 3, 2018.
- Confirm the total number of Units sold, including whether the 1,150,000 Unit overallotment option was exercised.
- Monitor the Company's progress in amending its Certificate of Incorporation to increase authorized shares, which is a condition precedent for the release of the waived warrants and restricted options.
- Review the full text of the Underwriting Agreement and Warrant forms (Exhibits 1.1, 4.1, 4.2, and 4.3) for specific adjustment provisions and expiration terms.